Lamm D L, DeHaven J I, Riggs D R, Ebert R F
Department of Urology, West Virginia University School of Medicine, Morgantown 26506-9251.
J Urol. 1993 Mar;149(3):648-52. doi: 10.1016/s0022-5347(17)36172-4.
Keyhole limpet hemocyanin (KLH) is a potent immunogen that is being evaluated as an immunotherapeutic alternative to BCG in the treatment of bladder cancer. In the mouse bladder tumor model (MBT2) intralesional KLH significantly reduced tumor incidence, growth rate, and mortality and exhibited antitumor activity similar to that achievable with BCG. Endotoxin contamination of KLH was not responsible for the antitumor activity, although endotoxin alone was shown to have anti-tumor activity in this animal model. Keyhole limpet hemocyanin is both safe and effective in the MBT2 model, and is an immunomodulator to consider for clinical trials.
钥孔血蓝蛋白（KLH）是一种强效免疫原，正被评估作为卡介苗（BCG）的免疫治疗替代方案用于膀胱癌治疗。在小鼠膀胱肿瘤模型（MBT2）中，瘤内注射KLH可显著降低肿瘤发生率、生长速率和死亡率，并展现出与BCG相当的抗肿瘤活性。KLH的内毒素污染并非其抗肿瘤活性的原因，尽管在此动物模型中单独的内毒素已显示具有抗肿瘤活性。钥孔血蓝蛋白在MBT2模型中既安全又有效，是一种值得考虑用于临床试验的免疫调节剂。
